首页 > 最新文献

Prostate Cancer最新文献

英文 中文
Investigating the Relationship of G-137C, C-607A, and A-1447G Polymorphisms in the Promoter of IL-18 and CXCL10 Inflammatory Genes with Prostate Cancer in an Iranian Population. 研究伊朗人群中 IL-18 和 CXCL10 炎症基因启动子中 G-137C、C-607A 和 A-1447G 多态性与前列腺癌的关系。
IF 2.3 Q3 ONCOLOGY Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI: 10.1155/2024/3997576
Nahid Ahmadi, Seyyed Amir Yasin Ahmadi, Abdolreza Kheirollahi, Farhad Shahsavar

Introduction: Genetic and environmental factors are involved in prostate cancer. The current study was conducted to study the relationship between G-137C, C-607A, and A-1447G polymorphisms in the promoter of IL-18 and CXCL10 inflammatory genes with prostate cancer.

Methods: As a genetic association study with a case-control design, the genomes of people living in Khorasan, Iran, were compared in two groups of cases and controls. The genotype of the A-1447G polymorphism present in the CXCL10 gene promoter was investigated by the PCR-RFLP method. PCR-SSP was used to study the genotype of G-137C and C-607A polymorphisms present in the IL-18 gene promoter. Odds ratio (OR) and 95% confidence interval (CI) were reported.

Results: One mutant allele in CXCL10 A-1447G polymorphism (AG) increased the chance of cancer (OR = 4.902, 95% CI = 2.70-8.87) and two mutant alleles (GG) increased more (OR = 7.174, 95% CI = 2.48-20.68). One mutant allele in IL-18 G-137C polymorphism (CG) increased the chance of cancer (OR = 5.583, 95% CI = 3.04-10.22) and two mutant alleles (CC) increased more (OR = 9.571, 95% CI = 3.10-29.46). One mutant allele in IL-18 C607A polymorphism (CA) increased the chance of cancer (OR = 5.359, 95% CI = 2.95-9.70) and two mutant alleles (AA) increased more (OR = 7.083, 95% CI = 2.61-19.15) (P < 0.001).

Conclusion: According to the results, the mutant alleles in polymorphisms CXCL10 A-1447G, IL-18 G-137C, and IL-18 C-607A alleles were associated with an increased chance of prostate cancer in this population.

简介前列腺癌与遗传和环境因素有关。本研究旨在探讨 IL-18 和 CXCL10 炎症基因启动子中的 G-137C、C-607A 和 A-1447G 多态性与前列腺癌的关系:作为一项采用病例对照设计的遗传关联研究,我们将伊朗呼罗珊地区居民的基因组分为病例组和对照组两组进行比较。采用 PCR-RFLP 方法调查了 CXCL10 基因启动子中 A-1447G 多态性的基因型。PCR-SSP用于研究IL-18基因启动子中G-137C和C-607A多态性的基因型。结果显示,CXL-18基因中有一个突变等位基因:结果:CXCL10 A-1447G多态性中的一个突变等位基因(AG)会增加患癌症的几率(OR = 4.902,95% CI = 2.70-8.87),而两个突变等位基因(GG)会增加患癌症的几率(OR = 7.174,95% CI = 2.48-20.68)。IL-18 G-137C 多态性中的一个突变等位基因(CG)会增加患癌症的几率(OR = 5.583,95% CI = 3.04-10.22),而两个突变等位基因(CC)会增加患癌症的几率(OR = 9.571,95% CI = 3.10-29.46)。IL-18 C607A多态性中的一个突变等位基因(CA)会增加患癌几率(OR = 5.359,95% CI = 2.95-9.70),而两个突变等位基因(AA)会增加患癌几率(OR = 7.083,95% CI = 2.61-19.15)(P < 0.001):结果显示,在该人群中,CXCL10 A-1447G、IL-18 G-137C和IL-18 C-607A等位基因的突变等位基因与前列腺癌发病几率增加有关。
{"title":"Investigating the Relationship of <i>G-137C</i>, <i>C-607A</i>, and <i>A-1447G</i> Polymorphisms in the Promoter of <i>IL-18</i> and <i>CXCL10</i> Inflammatory Genes with Prostate Cancer in an Iranian Population.","authors":"Nahid Ahmadi, Seyyed Amir Yasin Ahmadi, Abdolreza Kheirollahi, Farhad Shahsavar","doi":"10.1155/2024/3997576","DOIUrl":"10.1155/2024/3997576","url":null,"abstract":"<p><strong>Introduction: </strong>Genetic and environmental factors are involved in prostate cancer. The current study was conducted to study the relationship between <i>G-137C</i>, <i>C-607A</i>, and <i>A-1447G</i> polymorphisms in the promoter of <i>IL-18</i> and <i>CXCL10</i> inflammatory genes with prostate cancer.</p><p><strong>Methods: </strong>As a genetic association study with a case-control design, the genomes of people living in Khorasan, Iran, were compared in two groups of cases and controls. The genotype of the <i>A-1447G</i> polymorphism present in the <i>CXCL10</i> gene promoter was investigated by the PCR-RFLP method. PCR-SSP was used to study the genotype of <i>G-137C</i> and <i>C-607A</i> polymorphisms present in the <i>IL-18</i> gene promoter. Odds ratio (OR) and 95% confidence interval (CI) were reported.</p><p><strong>Results: </strong>One mutant allele in <i>CXCL10 A-1447G</i> polymorphism (AG) increased the chance of cancer (OR = 4.902, 95% CI = 2.70-8.87) and two mutant alleles (GG) increased more (OR = 7.174, 95% CI = 2.48-20.68). One mutant allele in <i>IL-18 G-137C</i> polymorphism (CG) increased the chance of cancer (OR = 5.583, 95% CI = 3.04-10.22) and two mutant alleles (CC) increased more (OR = 9.571, 95% CI = 3.10-29.46). One mutant allele in <i>IL-18 C607A</i> polymorphism (CA) increased the chance of cancer (OR = 5.359, 95% CI = 2.95-9.70) and two mutant alleles (AA) increased more (OR = 7.083, 95% CI = 2.61-19.15) (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>According to the results, the mutant alleles in polymorphisms <i>CXCL10 A-1447G</i>, <i>IL-18 G-137C</i>, and <i>IL-18 C-607A</i> alleles were associated with an increased chance of prostate cancer in this population.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2024 ","pages":"3997576"},"PeriodicalIF":2.3,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors. 评估前期使用雄激素受体信号抑制剂后对阉割耐药前列腺癌的二线治疗。
IF 2.3 Q3 ONCOLOGY Pub Date : 2024-08-05 eCollection Date: 2024-01-01 DOI: 10.1155/2024/9303603
Kazuro Kikkawa, Masahiro Tamaki, Kouhei Maruno, Tatsuya Hazama, Toshifumi Takahashi, Yuya Yamada, Masakazu Nakashima, Noriyuki Ito

This study evaluated the effects of docetaxel and androgen receptor signaling inhibitors as second-line treatments in patients with castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment. This study retrospectively evaluated the clinical outcomes of second-line treatment with docetaxel or androgen receptor signaling inhibitor in patients with castration-resistant prostate cancer who received first-line treatment with androgen receptor signaling inhibitors. Clinical backgrounds and outcomes were compared between docetaxel and androgen receptor signaling inhibitors as second-line treatment. Of 59 patients, 21 (35.6%) and 38 (64.4%) received docetaxel and androgen receptor signaling inhibitors as second-line treatment after first-line treatment with androgen receptor signaling inhibitors, respectively. In the second-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitor than with docetaxel (17 versus 6 months, P=0.014). In the first-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitors than with docetaxel (32 versus 25 months, P=0.014); however, no significant difference was found in the overall survival. Multivariate analysis revealed that there was no significant association between second-line treatment and survival, and first-line treatment with abiraterone was identified as a prognostic factor for progression-free survival. Subgroup analysis showed that the abiraterone-enzalutamide sequence was more effective than the other three sequences for progression-free survival and overall survival. This study suggests that second-line treatment with an androgen receptor signaling inhibitor for castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment may be more beneficial, particularly with abiraterone as the upfront treatment.

本研究评估了多西他赛和雄激素受体信号转导抑制剂作为二线治疗药物对接受雄激素受体信号转导抑制剂一线治疗后的阉割耐药前列腺癌患者的治疗效果。本研究回顾性评估了接受雄激素受体信号抑制剂一线治疗的阉割耐药前列腺癌患者接受多西他赛或雄激素受体信号抑制剂二线治疗的临床结果。比较了多西他赛和雄激素受体信号抑制剂作为二线治疗的临床背景和疗效。在59名患者中,分别有21人(35.6%)和38人(64.4%)在接受雄激素受体信号抑制剂一线治疗后接受了多西他赛和雄激素受体信号抑制剂的二线治疗。在二线治疗中,雄激素受体信号抑制剂的中位无进展生存期长于多西他赛(17个月对6个月,P=0.014)。在一线治疗中,雄激素受体信号抑制剂的中位无进展生存期长于多西他赛(32个月对25个月,P=0.014);但在总生存期方面没有发现显著差异。多变量分析显示,二线治疗与生存期之间没有显著关联,而阿比特龙一线治疗被认为是无进展生存期的预后因素。亚组分析显示,在无进展生存期和总生存期方面,阿比特龙-苯扎鲁胺序列比其他三种序列更有效。这项研究表明,在使用雄激素受体信号转导抑制剂作为一线治疗后,使用雄激素受体信号转导抑制剂对阉割耐药前列腺癌进行二线治疗可能更有益,尤其是使用阿比特龙作为前期治疗。
{"title":"Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors.","authors":"Kazuro Kikkawa, Masahiro Tamaki, Kouhei Maruno, Tatsuya Hazama, Toshifumi Takahashi, Yuya Yamada, Masakazu Nakashima, Noriyuki Ito","doi":"10.1155/2024/9303603","DOIUrl":"10.1155/2024/9303603","url":null,"abstract":"<p><p>This study evaluated the effects of docetaxel and androgen receptor signaling inhibitors as second-line treatments in patients with castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment. This study retrospectively evaluated the clinical outcomes of second-line treatment with docetaxel or androgen receptor signaling inhibitor in patients with castration-resistant prostate cancer who received first-line treatment with androgen receptor signaling inhibitors. Clinical backgrounds and outcomes were compared between docetaxel and androgen receptor signaling inhibitors as second-line treatment. Of 59 patients, 21 (35.6%) and 38 (64.4%) received docetaxel and androgen receptor signaling inhibitors as second-line treatment after first-line treatment with androgen receptor signaling inhibitors, respectively. In the second-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitor than with docetaxel (17 versus 6 months, <i>P</i>=0.014). In the first-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitors than with docetaxel (32 versus 25 months, <i>P</i>=0.014); however, no significant difference was found in the overall survival. Multivariate analysis revealed that there was no significant association between second-line treatment and survival, and first-line treatment with abiraterone was identified as a prognostic factor for progression-free survival. Subgroup analysis showed that the abiraterone-enzalutamide sequence was more effective than the other three sequences for progression-free survival and overall survival. This study suggests that second-line treatment with an androgen receptor signaling inhibitor for castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment may be more beneficial, particularly with abiraterone as the upfront treatment.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2024 ","pages":"9303603"},"PeriodicalIF":2.3,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health-Related and Psychosocial Factors Associated with Prostate Cancer Stage at Diagnosis among Males Participating in Alberta’s Tomorrow Project 参与艾伯塔省明天项目的男性在诊断时与前列腺癌阶段有关的健康和社会心理因素
Q3 ONCOLOGY Pub Date : 2023-11-10 DOI: 10.1155/2023/4426167
Michelle L. Aktary, Brittany Shewchuk, Qinggang Wang, Eric Hyndman, Lorraine Shack, Paula J. Robson, Karen A. Kopciuk
Prostate cancer (PCa) stage at diagnosis is an important predictor of cancer prognosis. In Canada, over one-quarter of males are diagnosed with advanced-stage PCa. Studies have identified several factors associated with PCa stage at diagnosis; however, evidence from Canada is limited. This study aimed to examine associations between sociodemographic characteristics, health history, health practices, and psychosocial factors and PCa stage at diagnosis among males participating in Alberta’s Tomorrow Project (ATP), a prospective cohort in Alberta, Canada. The study included males aged 35–69 years who developed PCa until January 2018. Factors associated with PCa stage at diagnosis were examined using partial proportional odds (PPO) ordinal regression models. A total of 410 males were diagnosed with PCa over the study period. A higher number of lifetime prostate-specific antigen tests were associated with earlier-stage PCa (OR 0.91, p = 0.02, 95% CI 0.83–0.99), while higher abdominal circumference (OR 1.02, p = 0.05, 95% CI 1.00–1.03), lower social support (OR 2.34, p < 0.01, 95% CI 1.31–4.17), and having children (OR 2.67, p < 0.01, 95% CI 1.38–5.16) were associated with later-stage disease. This study identified factors previously found in the literature as well as novel factors associated with PCa stage at diagnosis, which can help inform targets for cancer prevention programs to improve PCa prognosis.
前列腺癌(PCa)的诊断分期是预测预后的重要指标。在加拿大,超过四分之一的男性被诊断为晚期前列腺癌。研究已经确定了与前列腺癌诊断阶段相关的几个因素;然而,来自加拿大的证据有限。本研究旨在探讨社会人口统计学特征、健康史、健康习惯和心理社会因素与加拿大阿尔伯塔省明日计划(ATP)男性前列腺癌诊断阶段之间的关系。该研究包括年龄在35-69岁之间的男性,他们在2018年1月之前患有前列腺癌。诊断时与前列腺癌分期相关的因素采用部分比例odds (PPO)有序回归模型进行检验。在研究期间,共有410名男性被诊断为前列腺癌。终生前列腺特异性抗原检测次数较高与早期PCa相关(OR 0.91, p = 0.02, 95% CI 0.83-0.99),而较高的腹围(OR 1.02, p = 0.05, 95% CI 1.00-1.03),较低的社会支持(OR 2.34, p <0.01, 95% CI 1.31-4.17),有孩子(OR 2.67, p <0.01, 95% CI 1.38-5.16)与晚期疾病相关。本研究确定了先前文献中发现的因素以及与前列腺癌诊断阶段相关的新因素,这可以帮助告知癌症预防计划的目标,以改善前列腺癌预后。
{"title":"Health-Related and Psychosocial Factors Associated with Prostate Cancer Stage at Diagnosis among Males Participating in Alberta’s Tomorrow Project","authors":"Michelle L. Aktary, Brittany Shewchuk, Qinggang Wang, Eric Hyndman, Lorraine Shack, Paula J. Robson, Karen A. Kopciuk","doi":"10.1155/2023/4426167","DOIUrl":"https://doi.org/10.1155/2023/4426167","url":null,"abstract":"Prostate cancer (PCa) stage at diagnosis is an important predictor of cancer prognosis. In Canada, over one-quarter of males are diagnosed with advanced-stage PCa. Studies have identified several factors associated with PCa stage at diagnosis; however, evidence from Canada is limited. This study aimed to examine associations between sociodemographic characteristics, health history, health practices, and psychosocial factors and PCa stage at diagnosis among males participating in Alberta’s Tomorrow Project (ATP), a prospective cohort in Alberta, Canada. The study included males aged 35–69 years who developed PCa until January 2018. Factors associated with PCa stage at diagnosis were examined using partial proportional odds (PPO) ordinal regression models. A total of 410 males were diagnosed with PCa over the study period. A higher number of lifetime prostate-specific antigen tests were associated with earlier-stage PCa (OR 0.91, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M1\"> <mi>p</mi> </math> = 0.02, 95% CI 0.83–0.99), while higher abdominal circumference (OR 1.02, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M2\"> <mi>p</mi> </math> = 0.05, 95% CI 1.00–1.03), lower social support (OR 2.34, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M3\"> <mi>p</mi> </math> < 0.01, 95% CI 1.31–4.17), and having children (OR 2.67, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M4\"> <mi>p</mi> </math> < 0.01, 95% CI 1.38–5.16) were associated with later-stage disease. This study identified factors previously found in the literature as well as novel factors associated with PCa stage at diagnosis, which can help inform targets for cancer prevention programs to improve PCa prognosis.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"78 17","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135093089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive Dysfunction in Patients Treated with Androgen Deprivation Therapy: A Multimodality Functional Imaging Study to Evaluate Neuroinflammation. 雄激素剥夺治疗患者的认知功能障碍:评估神经炎症的多模态功能成像研究。
IF 4.2 Q3 ONCOLOGY Pub Date : 2023-10-18 eCollection Date: 2023-01-01 DOI: 10.1155/2023/6641707
Azeem Saleem, Syed Imran Ali Shah, Stephen A Mangar, Christopher Coello, Matthew B Wall, Gaia Rizzo, Terry Jones, Patricia M Price

Background: Androgen deprivation therapy (ADT) for prostate cancer is implicated as a possible cause of cognitive impairment (CI). CI in dementia and Alzheimer's disease is associated with neuroinflammation. In this study, we investigated a potential role of neuroinflammation in ADT-related CI.

Methods: Patients with prostate cancer on ADT for ≥3 months were categorized as having ADT-emergent CI or normal cognition (NC) based on self-report at interview. Neuroinflammation was evaluated using positron emission tomography (PET) with the translocator protein (TSPO) radioligand [11C]-PBR28. [11C]-PBR28 uptake in various brain regions was quantified as standardized uptake value (SUVR, normalized to cerebellum) and related to blood oxygen level-dependent functional magnetic resonance imaging (BOLD-fMRI) choice-reaction time task (CRT) activation maps.

Results: Eleven patients underwent PET: four with reported CI (rCI), six with reported NC (rNC), and one status unrecorded. PET did not reveal any between-group differences in SUVR regionally or globally. There was no difference between groups on brain activation to the CRT. Regardless of the reported cognitive status, there was strong correlation between PET-TSPO signal and CRT activation in the hippocampus, amygdala, and medial cortex.

Conclusions: We found no difference in neuroinflammation measured by PET-TSPO between patients with rCI and rNC. However, we speculate that the strong correlation between TSPO uptake and BOLD-fMRI activation in brain regions involved in memory and known to have high androgen-receptor expression mediating plasticity (hippocampus and amygdala) might reflect inflammatory effects of ADT with compensatory upregulated/increased synaptic functions. Further studies of this imaging readout are warranted to investigate ADT-related CI.

背景:前列腺癌症的雄激素剥夺治疗(ADT)可能是认知障碍(CI)的一个原因。痴呆和阿尔茨海默病的CI与神经炎症有关。在本研究中,我们研究了神经炎症在ADT相关CI中的潜在作用。方法:癌症前列腺患者ADT≥3 根据访谈时的自我报告,月被归类为ADT突发CI或正常认知(NC)。使用正电子发射断层扫描(PET)和转运蛋白(TSPO)放射性配体[11C]-PBR28评估神经炎症。[11C]-PBR28在不同大脑区域的摄取被量化为标准摄取值(SUVR,标准化为小脑),并与血氧水平依赖性功能磁共振成像(BOLD-fMRI)选择反应时间任务(CRT)激活图相关。结果:11例患者接受了PET检查:4例报告CI(rCI),6例报告NC(rNC),1例未记录状态。PET未显示SUVR在区域或全球范围内的任何组间差异。两组对CRT的大脑激活没有差异。无论报告的认知状态如何,PET-TSPO信号与海马、杏仁核和内侧皮层的CRT激活之间都存在很强的相关性。结论:PET-TSPO检测rCI和rNC患者的神经炎症没有差异。然而,我们推测,TSPO摄取与大脑中参与记忆且已知具有高雄激素受体表达介导可塑性的区域(海马体和杏仁核)的BOLD fMRI激活之间的强相关性可能反映了ADT的炎症效应,其具有代偿性上调/增加的突触功能。有必要对这种成像读数进行进一步研究,以研究ADT相关的CI。
{"title":"Cognitive Dysfunction in Patients Treated with Androgen Deprivation Therapy: A Multimodality Functional Imaging Study to Evaluate Neuroinflammation.","authors":"Azeem Saleem,&nbsp;Syed Imran Ali Shah,&nbsp;Stephen A Mangar,&nbsp;Christopher Coello,&nbsp;Matthew B Wall,&nbsp;Gaia Rizzo,&nbsp;Terry Jones,&nbsp;Patricia M Price","doi":"10.1155/2023/6641707","DOIUrl":"10.1155/2023/6641707","url":null,"abstract":"<p><strong>Background: </strong>Androgen deprivation therapy (ADT) for prostate cancer is implicated as a possible cause of cognitive impairment (CI). CI in dementia and Alzheimer's disease is associated with neuroinflammation. In this study, we investigated a potential role of neuroinflammation in ADT-related CI.</p><p><strong>Methods: </strong>Patients with prostate cancer on ADT for ≥3 months were categorized as having ADT-emergent CI or normal cognition (NC) based on self-report at interview. Neuroinflammation was evaluated using positron emission tomography (PET) with the translocator protein (TSPO) radioligand [<sup>11</sup>C]-PBR28. [<sup>11</sup>C]-PBR28 uptake in various brain regions was quantified as standardized uptake value (SUVR, normalized to cerebellum) and related to blood oxygen level-dependent functional magnetic resonance imaging (BOLD-fMRI) choice-reaction time task (CRT) activation maps.</p><p><strong>Results: </strong>Eleven patients underwent PET: four with reported CI (rCI), six with reported NC (rNC), and one status unrecorded. PET did not reveal any between-group differences in SUVR regionally or globally. There was no difference between groups on brain activation to the CRT. Regardless of the reported cognitive status, there was strong correlation between PET-TSPO signal and CRT activation in the hippocampus, amygdala, and medial cortex.</p><p><strong>Conclusions: </strong>We found no difference in neuroinflammation measured by PET-TSPO between patients with rCI and rNC. However, we speculate that the strong correlation between TSPO uptake and BOLD-fMRI activation in brain regions involved in memory and known to have high androgen-receptor expression mediating plasticity (hippocampus and amygdala) might reflect inflammatory effects of ADT with compensatory upregulated/increased synaptic functions. Further studies of this imaging readout are warranted to investigate ADT-related CI.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2023 ","pages":"6641707"},"PeriodicalIF":4.2,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54230785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review. 前列腺癌脑转移的临床、诊断、治疗和预后特征:一项系统综述。
IF 4.2 Q3 ONCOLOGY Pub Date : 2022-01-01 DOI: 10.1155/2022/5324600
Seyyedmohammadsadeq Mirmoeeni, Amirhossein Azari Jafari, Muffaqam Shah, Fateme Salemi, Seyedeh Zohreh Hashemi, Ali Seifi

Aim: Prostate cancer (PCa) is the second most common nonskin malignancy and the second most common cause of cancer-related deaths in men. The most common site of metastasis in PCa is the axial skeleton which may lead to back pain or pathological fractures. Hematogenous spread to the brain and involvement of the central nervous system (CNS) are a rare occurrence. However, failed androgen deprivation therapy (ADT) may facilitate such a spread resulting in an advanced metastatic stage of PCa, which carries a poor prognosis.

Methods: In this systematic review, we searched the PubMed, Scopus, and Web of Science online databases based on the PRISMA guideline and used all the medical subject headings (MeSH) in terms of the following search line: ("Brain Neoplasms" OR "Central Nervous System Neoplasms") and ("Prostatic Neoplasms" OR "Prostate"). Related studies were identified and reviewed.

Results: A total of 59 eligible studies (902 patients) were included in this systematic review. In order to gain a deeper understanding, we extracted and presented the data from included articles based on clinical manifestations, diagnostic methods, therapeutic approaches, and prognostic status of PCa patients having BMs.

Conclusion: We have demonstrated the current knowledge regarding the mechanism, clinical manifestations, diagnostic methods, therapeutic approaches, and prognosis of BMs in PCa. These data shed more light on the way to help clinicians and physicians to understand, diagnose, and manage BMs in PCa patients better.

目的:前列腺癌(PCa)是第二常见的非皮肤恶性肿瘤,也是男性癌症相关死亡的第二大常见原因。前列腺癌最常见的转移部位是中轴骨骼,可导致背部疼痛或病理性骨折。血液扩散到大脑和累及中枢神经系统(CNS)是罕见的发生。然而,失败的雄激素剥夺治疗(ADT)可能促进这种扩散,导致晚期转移阶段的前列腺癌,其预后较差。方法:在本系统综述中,我们根据PRISMA指南检索PubMed、Scopus和Web of Science在线数据库,并根据以下搜索线使用所有医学主题标题(MeSH):“脑肿瘤”或“中枢神经系统肿瘤”和“前列腺肿瘤”或“前列腺”。对相关研究进行了鉴定和回顾。结果:本系统综述共纳入59项符合条件的研究(902例患者)。为了获得更深入的理解,我们根据PCa合并脑转移患者的临床表现、诊断方法、治疗方法和预后状况,从纳入的文章中提取并呈现数据。结论:我们对前列腺癌脑转移的机制、临床表现、诊断方法、治疗方法和预后等方面的现有知识进行了论证。这些数据有助于临床医生更好地理解、诊断和管理前列腺癌患者的脑转移。
{"title":"The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review.","authors":"Seyyedmohammadsadeq Mirmoeeni,&nbsp;Amirhossein Azari Jafari,&nbsp;Muffaqam Shah,&nbsp;Fateme Salemi,&nbsp;Seyedeh Zohreh Hashemi,&nbsp;Ali Seifi","doi":"10.1155/2022/5324600","DOIUrl":"https://doi.org/10.1155/2022/5324600","url":null,"abstract":"<p><strong>Aim: </strong>Prostate cancer (PCa) is the second most common nonskin malignancy and the second most common cause of cancer-related deaths in men. The most common site of metastasis in PCa is the axial skeleton which may lead to back pain or pathological fractures. Hematogenous spread to the brain and involvement of the central nervous system (CNS) are a rare occurrence. However, failed androgen deprivation therapy (ADT) may facilitate such a spread resulting in an advanced metastatic stage of PCa, which carries a poor prognosis.</p><p><strong>Methods: </strong>In this systematic review, we searched the PubMed, Scopus, and Web of Science online databases based on the PRISMA guideline and used all the medical subject headings (MeSH) in terms of the following search line: (\"Brain Neoplasms\" OR \"Central Nervous System Neoplasms\") and (\"Prostatic Neoplasms\" OR \"Prostate\"). Related studies were identified and reviewed.</p><p><strong>Results: </strong>A total of 59 eligible studies (902 patients) were included in this systematic review. In order to gain a deeper understanding, we extracted and presented the data from included articles based on clinical manifestations, diagnostic methods, therapeutic approaches, and prognostic status of PCa patients having BMs.</p><p><strong>Conclusion: </strong>We have demonstrated the current knowledge regarding the mechanism, clinical manifestations, diagnostic methods, therapeutic approaches, and prognosis of BMs in PCa. These data shed more light on the way to help clinicians and physicians to understand, diagnose, and manage BMs in PCa patients better.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2022 ","pages":"5324600"},"PeriodicalIF":4.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso. 布基纳法索前列腺癌患者ELAC2基因Ser217Leu和Ala541Thr变异的携带及其危险因素
IF 4.2 Q3 ONCOLOGY Pub Date : 2022-01-01 DOI: 10.1155/2022/3610089
Aïda Djé Djénèba Traoré, Bienvenu Désiré Ky, Lassina Traoré, Théodora M Zohoncon, Abdou Azaque Zouré, Albert Théophane Yonli, Herman Karim Sombié, Pegdwendé Abel Sorgho, Bapio Valery Jean Télesphore Elvira Bazié, Sessi Frida Appoline Tovo, Essonan Kadanga, Bélélé Siméon Bakyono, Kalifou Traore, Teega-Wendé Clarisse Ouédraogo, Florencia W Djigma, Jacques Simpore

Background: Genetic factors are one of the significant contributors to prostate cancer (PCa) development, and hereditary prostate cancer 2 (HPC2) locus gene ELAC2 is considered a PCa susceptibility region. The HPC2/ELAC2 gene has been identified by linkage analysis in familial prostate cancer patients in the United States but has never been studied in Burkina Faso. The objective of the present study was to analyze the carriage of the C650T (Ser217Leu) and G1621A (Ala541Thr) mutations of the ELAC2 gene and the risk factors in prostate cancer patients in Burkina Faso.

Methods: This case-control study included 76 participants, including 38 histologically confirmed prostate cancer cases and 38 healthy controls without prostate abnormalities. PCR combined with restriction fragment length polymorphism (RFLP) was used to characterize the genotypes of the Ser217Leu and Ala541Thr polymorphisms of the ELAC2 gene. The correlations between the different genotypes and risk factors for prostate cancer were investigated.

Results: The C650T mutation was present in 44.73% of prostate cancer cases and 47.37% of controls. The G1621A mutation was present in 26.32% of prostate cancer cases and 15.79% of controls. We did not detect an association between prostate cancer risk and the Ser217Leu (p=0.972) and Ala541Thr (p=0.267) variants of the ELAC2 gene. Also, the two ELAC2 SNPs did not correlate with clinical stage, prostate-specific antigen (PSA) level at diagnosis, or the Gleason score on biopsies. However, we found that 100% of homozygous carriers of the T650 mutation have an A1621 mutation (p ≤ 0.001).

Conclusion: Ser217Leu and Ala541Thr polymorphisms of ELAC2, considered alone or in combination, are not associated with prostate cancer risk.

背景:遗传因素是前列腺癌(PCa)发生的重要因素之一,遗传性前列腺癌2 (HPC2)基因座基因ELAC2被认为是前列腺癌的易感区域。HPC2/ELAC2基因已在美国家族性前列腺癌患者中通过连锁分析确定,但从未在布基纳法索进行过研究。本研究的目的是分析布基纳法索前列腺癌患者ELAC2基因C650T (Ser217Leu)和G1621A (Ala541Thr)突变的携带情况及其危险因素。方法:本病例对照研究纳入76例受试者,其中组织学证实的前列腺癌患者38例,前列腺无异常的健康对照38例。采用PCR结合限制性片段长度多态性(RFLP)对ELAC2基因Ser217Leu和Ala541Thr多态性进行基因型鉴定。研究不同基因型与前列腺癌危险因素的相关性。结果:C650T突变存在于44.73%的前列腺癌病例和47.37%的对照组中。G1621A突变存在于26.32%的前列腺癌病例和15.79%的对照组中。我们没有发现前列腺癌风险与ELAC2基因的Ser217Leu (p=0.972)和Ala541Thr (p=0.267)变异之间的关联。此外,两个ELAC2 snp与临床分期、诊断时的前列腺特异性抗原(PSA)水平或活检时的Gleason评分无关。然而,我们发现100%的T650突变纯合携带者都有A1621突变(p≤0.001)。结论:ELAC2的Ser217Leu和Ala541Thr多态性,单独或联合考虑,与前列腺癌的风险无关。
{"title":"Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso.","authors":"Aïda Djé Djénèba Traoré,&nbsp;Bienvenu Désiré Ky,&nbsp;Lassina Traoré,&nbsp;Théodora M Zohoncon,&nbsp;Abdou Azaque Zouré,&nbsp;Albert Théophane Yonli,&nbsp;Herman Karim Sombié,&nbsp;Pegdwendé Abel Sorgho,&nbsp;Bapio Valery Jean Télesphore Elvira Bazié,&nbsp;Sessi Frida Appoline Tovo,&nbsp;Essonan Kadanga,&nbsp;Bélélé Siméon Bakyono,&nbsp;Kalifou Traore,&nbsp;Teega-Wendé Clarisse Ouédraogo,&nbsp;Florencia W Djigma,&nbsp;Jacques Simpore","doi":"10.1155/2022/3610089","DOIUrl":"https://doi.org/10.1155/2022/3610089","url":null,"abstract":"<p><strong>Background: </strong>Genetic factors are one of the significant contributors to prostate cancer (PCa) development, and hereditary prostate cancer 2 (HPC2) locus gene ELAC2 is considered a PCa susceptibility region. The HPC2/ELAC2 gene has been identified by linkage analysis in familial prostate cancer patients in the United States but has never been studied in Burkina Faso. The objective of the present study was to analyze the carriage of the C650T (Ser217Leu) and G1621A (Ala541Thr) mutations of the ELAC2 gene and the risk factors in prostate cancer patients in Burkina Faso.</p><p><strong>Methods: </strong>This case-control study included 76 participants, including 38 histologically confirmed prostate cancer cases and 38 healthy controls without prostate abnormalities. PCR combined with restriction fragment length polymorphism (RFLP) was used to characterize the genotypes of the Ser217Leu and Ala541Thr polymorphisms of the ELAC2 gene. The correlations between the different genotypes and risk factors for prostate cancer were investigated.</p><p><strong>Results: </strong>The C650T mutation was present in 44.73% of prostate cancer cases and 47.37% of controls. The G1621A mutation was present in 26.32% of prostate cancer cases and 15.79% of controls. We did not detect an association between prostate cancer risk and the Ser217Leu (<i>p</i>=0.972) and Ala541Thr (<i>p</i>=0.267) variants of the ELAC2 gene. Also, the two ELAC2 SNPs did not correlate with clinical stage, prostate-specific antigen (PSA) level at diagnosis, or the Gleason score on biopsies. However, we found that 100% of homozygous carriers of the T650 mutation have an A1621 mutation (<i>p</i> ≤ 0.001).</p><p><strong>Conclusion: </strong>Ser217Leu and Ala541Thr polymorphisms of ELAC2, considered alone or in combination, are not associated with prostate cancer risk.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2022 ","pages":"3610089"},"PeriodicalIF":4.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10533994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. 阿帕鲁胺加雄激素剥夺治疗与阿帕鲁胺单药治疗与雄激素剥夺单药治疗在生化复发前列腺癌患者中的随机、开放标签2期研究
IF 4.2 Q3 ONCOLOGY Pub Date : 2022-01-01 DOI: 10.1155/2022/5454727
Rahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, Celestia S Higano, Alan H Bryce, Angela Lopez-Gitlitz, Sharon A McCarthy, Branko Miladinovic, Kelly McQuarrie, Shibu Thomas, Ke Zhang, Eric J Small

Purpose: This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC). Materials and Methods. Patients with BCR PC after primary definitive therapy and prostate-specific antigen (PSA) doubling time ≤12 months were randomized to open-label apalutamide (240 mg/d) alone, apalutamide plus ADT, or ADT alone (1 : 1:1 ratio) for 12 months followed by a 12-month observation period (NCT01790126). Mean changes from baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) at 12 months (primary endpoint) and other prespecified assessments of health-related quality of life (HRQoL), PSA nadir, time to PSA progression, time to testosterone recovery, recovered testosterone >150 ng/dL without PSA progression at 24 months, and molecular markers were evaluated.

Results: In 90 enrolled patients (apalutamide plus ADT (n = 31), apalutamide (n = 29), ADT (n = 30)), FACT-P at 12 months was not significantly different between apalutamide, ADT and apalutamide, and ADT groups. Addition of apalutamide to ADT prolonged time to PSA progression but this change did not reach statistical significance (hazard ratio (HR): 0.56, 95% confidence interval (CI): 0.23-1.36, P=0.196); time to testosterone recovery was similar in the ADT-containing groups. In apalutamide plus ADT, apalutamide, and ADT groups, 37.9%, 37.0%, and 19.2% of patients, respectively, had testosterone >150 ng/dL at 24 months without confirmed PSA progression. Of the few biomarkers expressed in blood, EPHA3 was significantly associated with shorter time to PSA progression (P=0.02) in the overall population.

Conclusions: HRQoL was similar in patients treated with apalutamide alone, ADT alone, or their combination, although apalutamide plus ADT did not demonstrate statistically significant noninferiority in change from baseline in overall HRQoL. The aggregated efficacy and safety outcomes support further evaluation of apalutamide plus ADT in BCR PC.

目的:这项随机2期研究旨在评估阿帕鲁胺联合或不联合雄激素剥夺治疗(ADT)对生化复发性前列腺癌(BCR PC)的治疗效果。材料与方法。原发性确诊治疗后,前列腺特异性抗原(PSA)翻倍时间≤12个月的BCR PC患者,随机分为单独使用开放标签阿帕鲁胺(240 mg/d)、阿帕鲁胺加ADT或单独使用ADT(1:1比例)治疗12个月,然后进行12个月的观察(NCT01790126)。12个月(主要终点)时癌症治疗-前列腺功能评估(FACT-P)和其他预先规定的健康相关生活质量(HRQoL)、PSA最低点、PSA进展时间、睾酮恢复时间、24个月时恢复睾酮>150 ng/dL且PSA无进展的平均变化,以及分子标记物进行评估。结果:90例入选患者(阿帕鲁胺加ADT (n = 31),阿帕鲁胺加ADT (n = 29), ADT (n = 30)), 12个月时的FACT-P在阿帕鲁胺、ADT加阿帕鲁胺组和ADT组之间无显著差异。在ADT中加入阿帕鲁胺延长了PSA进展的时间,但这种变化没有达到统计学意义(风险比(HR): 0.56, 95%可信区间(CI): 0.23-1.36, P=0.196);睾酮恢复时间与adt组相似。在阿帕鲁胺加ADT、阿帕鲁胺和ADT组中,分别有37.9%、37.0%和19.2%的患者在24个月时睾酮>150 ng/dL,未确诊PSA进展。在血液中表达的少数生物标志物中,EPHA3与总体人群中较短的PSA进展时间显著相关(P=0.02)。结论:单独使用阿帕鲁胺、单独使用ADT或联合使用阿帕鲁胺治疗的患者的HRQoL相似,尽管阿帕鲁胺加ADT在总体HRQoL的基线变化方面没有统计学意义上的显着非劣效性。综合疗效和安全性结果支持进一步评估阿帕鲁胺加ADT治疗BCR PC。
{"title":"Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.","authors":"Rahul Aggarwal,&nbsp;Joshi J Alumkal,&nbsp;Russell Z Szmulewitz,&nbsp;Celestia S Higano,&nbsp;Alan H Bryce,&nbsp;Angela Lopez-Gitlitz,&nbsp;Sharon A McCarthy,&nbsp;Branko Miladinovic,&nbsp;Kelly McQuarrie,&nbsp;Shibu Thomas,&nbsp;Ke Zhang,&nbsp;Eric J Small","doi":"10.1155/2022/5454727","DOIUrl":"https://doi.org/10.1155/2022/5454727","url":null,"abstract":"<p><strong>Purpose: </strong>This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC)<i>. Materials and Methods</i>. Patients with BCR PC after primary definitive therapy and prostate-specific antigen (PSA) doubling time ≤12 months were randomized to open-label apalutamide (240 mg/d) alone, apalutamide plus ADT, or ADT alone (1 : 1:1 ratio) for 12 months followed by a 12-month observation period (NCT01790126). Mean changes from baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) at 12 months (primary endpoint) and other prespecified assessments of health-related quality of life (HRQoL), PSA nadir, time to PSA progression, time to testosterone recovery, recovered testosterone >150 ng/dL without PSA progression at 24 months, and molecular markers were evaluated.</p><p><strong>Results: </strong>In 90 enrolled patients (apalutamide plus ADT (<i>n</i> = 31), apalutamide (<i>n</i> = 29), ADT (<i>n</i> = 30)), FACT-P at 12 months was not significantly different between apalutamide, ADT and apalutamide, and ADT groups. Addition of apalutamide to ADT prolonged time to PSA progression but this change did not reach statistical significance (hazard ratio (HR): 0.56, 95% confidence interval (CI): 0.23-1.36, <i>P</i>=0.196); time to testosterone recovery was similar in the ADT-containing groups. In apalutamide plus ADT, apalutamide, and ADT groups, 37.9%, 37.0%, and 19.2% of patients, respectively, had testosterone >150 ng/dL at 24 months without confirmed PSA progression. Of the few biomarkers expressed in blood, <i>EPHA3</i> was significantly associated with shorter time to PSA progression (<i>P</i>=0.02) in the overall population.</p><p><strong>Conclusions: </strong>HRQoL was similar in patients treated with apalutamide alone, ADT alone, or their combination, although apalutamide plus ADT did not demonstrate statistically significant noninferiority in change from baseline in overall HRQoL. The aggregated efficacy and safety outcomes support further evaluation of apalutamide plus ADT in BCR PC.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2022 ","pages":"5454727"},"PeriodicalIF":4.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9262848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cosmetic Appeal, HRQoL, and Effectiveness of Simple and Pseudotesticular Techniques of Orchidectomy in Prostate Cancer. 前列腺癌单纯睾丸切除术和假睾丸切除术的美容效果、HRQoL 和有效性。
IF 4.2 Q3 ONCOLOGY Pub Date : 2021-11-26 eCollection Date: 2021-01-01 DOI: 10.1155/2021/9968570
Ijeoma N C Chibuzo, Augustine O Takure, Olayiwola B Shittu, Linus I Okeke

Introduction: Orchidectomy is the most cost-effective means of hormonal therapy for locally advanced or metastatic prostate cancer (LAMP). However, cost-effectiveness should not detract from health-related quality of life (HRQoL) considerations. Bilateral simple orchidectomy (BSO) has been linked to negative psychometric deficits from an empty scrotum. This study compared the HRQoL, therapeutic efficacy, and cosmetic appeal of BSO with endogenous pseudotesticular techniques of bilateral subcapsular orchidectomy (BSCO) and bilateral-epididymal-sparing orchidectomy (BESO). Research Design. Nigerian patients with LAMP were randomised into three surgical arms: BSO, BSCO, and BESO. Expanded Prostate Cancer Index Composite-26 HRQoL and sociodemographic questionnaires were administered before and three months after orchidectomy. Serum testosterone and PSA were measured at 0, 1, 2, and 3 hours; 7 days; and 3 months postoperatively. Pseudotesticular volumes and cosmetic appeal were assessed at 3 months.

Result: Sixty-three patients were recruited (24 BSO, 21 BSCO, 18 BESO), 73% of whom were low-income earners. There was no significant difference in the procedure cost nor the PSA or testosterone nadirs achieved over the three-month follow-up period (11.3, 12.6, 15.2 ng/ml (p=0.667) and 0.44, 0.64, 0.79 nmol/l (p=0.603) respectively). Those with pseudotesticles (BSCO, BESO) felt less emasculated (p=0.010). BSCO produced the least sexual bother, highest sexual function, and largest pseudotesticular volumes. The cosmetic appeal scores were similar between groups (77.9 ± 22.8, 81 ± 13.9, and 81.9 ± 22.5, respectively, p=0.858).

Conclusion: Endogenous pseudotesticular techniques, when compared with BSO, reduce the negative psychological impact experienced by patients without increasing costs. BSCO produced the best pseudotesticular volumes and postoperative sexual function. This study is registered with the ClinicalTrials.gov of the National Institute of Health U.S. National Library of Medicine as TEPSO study, NCT03744494: Comparison of the Therapeutic Efficacy and Patient Satisfaction of Three Techniques of Bilateral Orchidectomy in Prostate Cancer Patients of a Nigerian Sub-population. Registration completed on 16th of November, 2018 (registered retrospectively) NCT03744494.

简介:睾丸切除术是治疗局部晚期或转移性前列腺癌(LAMP)最具成本效益的激素疗法。然而,成本效益不应影响对健康相关生活质量(HRQoL)的考虑。双侧单纯睾丸切除术(BSO)与阴囊空虚造成的心理测量缺陷有关。本研究比较了 BSO 与双侧囊下睾丸切除术 (BSCO) 和双侧睾丸切除术 (BESO) 等内源性假睾丸技术的 HRQoL、疗效和外观吸引力。研究设计。尼日利亚 LAMP 患者被随机分为三个手术组:BSO、BSCO 和 BESO。在睾丸切除术前和术后三个月分别进行了前列腺癌扩展指数 Composite-26 HRQoL 和社会人口学问卷调查。血清睾酮和 PSA 分别在术后 0、1、2 和 3 小时、7 天和 3 个月进行测量。3个月后对假睾丸体积和外观进行评估:共招募了 63 名患者(24 名 BSO、21 名 BSCO、18 名 BESO),其中 73% 为低收入者。在三个月的随访期间,手术费用、PSA 或睾酮阈值均无明显差异(分别为 11.3、12.6、15.2 纳克/毫升(P=0.667)和 0.44、0.64、0.79 毫摩尔/升(P=0.603))。有假睾丸(BSCO、BESO)的人较少感到男性阳痿(P=0.010)。BSCO 产生的性困扰最小、性功能最高、假睾丸体积最大。各组的外观吸引力评分相似(分别为 77.9 ± 22.8、81 ± 13.9 和 81.9 ± 22.5,P=0.858):结论:与 BSO 相比,内源性假睾丸技术可在不增加费用的情况下减少患者的负面心理影响。BSCO产生的假睾丸体积和术后性功能最佳。本研究已在美国国立卫生研究院国家医学图书馆的 ClinicalTrials.gov 登记为 TEPSO 研究,NCT03744494:尼日利亚亚群前列腺癌患者双侧睾丸切除术三种技术的疗效和患者满意度比较。2018年11月16日完成注册(回顾性注册)NCT03744494。
{"title":"Cosmetic Appeal, HRQoL, and Effectiveness of Simple and Pseudotesticular Techniques of Orchidectomy in Prostate Cancer.","authors":"Ijeoma N C Chibuzo, Augustine O Takure, Olayiwola B Shittu, Linus I Okeke","doi":"10.1155/2021/9968570","DOIUrl":"10.1155/2021/9968570","url":null,"abstract":"<p><strong>Introduction: </strong>Orchidectomy is the most cost-effective means of hormonal therapy for locally advanced or metastatic prostate cancer (LAMP). However, cost-effectiveness should not detract from health-related quality of life (HRQoL) considerations. Bilateral simple orchidectomy (BSO) has been linked to negative psychometric deficits from an empty scrotum. This study compared the HRQoL, therapeutic efficacy, and cosmetic appeal of BSO with endogenous pseudotesticular techniques of bilateral subcapsular orchidectomy (BSCO) and bilateral-epididymal-sparing orchidectomy (BESO). <i>Research Design</i>. Nigerian patients with LAMP were randomised into three surgical arms: BSO, BSCO, and BESO. Expanded Prostate Cancer Index Composite-26 HRQoL and sociodemographic questionnaires were administered before and three months after orchidectomy. Serum testosterone and PSA were measured at 0, 1, 2, and 3 hours; 7 days; and 3 months postoperatively. Pseudotesticular volumes and cosmetic appeal were assessed at 3 months.</p><p><strong>Result: </strong>Sixty-three patients were recruited (24 BSO, 21 BSCO, 18 BESO), 73% of whom were low-income earners. There was no significant difference in the procedure cost nor the PSA or testosterone nadirs achieved over the three-month follow-up period (11.3, 12.6, 15.2 ng/ml (<i>p</i>=0.667) and 0.44, 0.64, 0.79 nmol/l (<i>p</i>=0.603) respectively). Those with pseudotesticles (BSCO, BESO) felt less emasculated (<i>p</i>=0.010). BSCO produced the least sexual bother, highest sexual function, and largest pseudotesticular volumes. The cosmetic appeal scores were similar between groups (77.9 ± 22.8, 81 ± 13.9, and 81.9 ± 22.5, respectively, <i>p</i>=0.858).</p><p><strong>Conclusion: </strong>Endogenous pseudotesticular techniques, when compared with BSO, reduce the negative psychological impact experienced by patients without increasing costs. BSCO produced the best pseudotesticular volumes and postoperative sexual function. This study is registered with the ClinicalTrials.gov of the National Institute of Health U.S. National Library of Medicine as TEPSO study, NCT03744494: Comparison of the Therapeutic Efficacy and Patient Satisfaction of Three Techniques of Bilateral Orchidectomy in Prostate Cancer Patients of a Nigerian Sub-population. Registration completed on 16<sup>th</sup> of November, 2018 (registered retrospectively) NCT03744494.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2021 ","pages":"9968570"},"PeriodicalIF":4.2,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39948475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relevance of Interleukins 6 and 8 Single Nucleotide Polymorphisms in Prostate Cancer: A Multicenter Study. 白细胞介素6和8单核苷酸多态性与前列腺癌的相关性:一项多中心研究。
IF 4.2 Q3 ONCOLOGY Pub Date : 2021-07-06 eCollection Date: 2021-01-01 DOI: 10.1155/2021/3825525
Amany A Ghazy, Mohammed Jayed Alenzi

The diverse roles of cytokines as IL-6 and IL-8 have been studied in terms of their SNPs in many diseases but their role in prostate cancer (PCa) is still uncertain. Aim. To determine the relevance of IL-6 rs1800795 SNP and/or IL-8 rs2227306 SNP with prostate cancer's risk. Subjects and Methods. 40 PCa patients, 40 benign prostate hyperplasia (BPH) patients, and 40-age-matched-control group were enrolled in the study. Genotyping of IL-6 rs1800795 (G/C) SNP and IL-8 rs2227306 (C/T) SNP was determined using real-time PCR. Results. High frequency of IL-6 rs1800795GG and IL-8 rs2227306CC genotypes was noticed among PCa patients with associated OR 10.091 and 8.143, respectively. Comparisons based on allele frequencies revealed that IL-6G and IL-8C alleles are more frequent among PCa patients than other groups. Presence of IL-6 rs1800795G and IL-8 rs2227306C alleles in the same patient increase PCa risk by 16.7 times. Statistical correlations between PSA ratio and both of IL-6 and IL-8 SNP did not show any significant relation among PCa patients. Conclusion. IL-6 rs1800795G and IL-8 rs2227306C alleles could be considered risk factors for PCa development, particularly if presented together. However, no relation was found between both cytokines SNP and severity of prostate cancer.

细胞因子如IL-6和IL-8在许多疾病中的snp作用已被研究,但其在前列腺癌(PCa)中的作用仍不确定。的目标。确定IL-6 rs1800795 SNP和/或IL-8 rs2227306 SNP与前列腺癌风险的相关性。研究对象与方法:选取40例PCa患者、40例良性前列腺增生(BPH)患者和40例年龄匹配的对照组。实时荧光定量PCR检测IL-6 rs1800795 (G/C) SNP和IL-8 rs2227306 (C/T) SNP的基因分型。结果。IL-6 rs1800795GG和IL-8 rs2227306CC基因型在PCa患者中的发生率较高,相关OR分别为10.091和8.143。基于等位基因频率的比较显示,IL-6G和IL-8C等位基因在PCa患者中比其他组更常见。同一患者中IL-6 rs1800795G和IL-8 rs2227306C等位基因的存在使PCa风险增加16.7倍。PSA比值与IL-6、IL-8 SNP在PCa患者中均无统计学相关性。结论。IL-6 rs1800795G和IL-8 rs2227306C等位基因可以被认为是前列腺癌发展的危险因素,特别是如果同时出现。然而,细胞因子SNP与前列腺癌的严重程度之间没有相关性。
{"title":"Relevance of Interleukins 6 and 8 Single Nucleotide Polymorphisms in Prostate Cancer: A Multicenter Study.","authors":"Amany A Ghazy,&nbsp;Mohammed Jayed Alenzi","doi":"10.1155/2021/3825525","DOIUrl":"https://doi.org/10.1155/2021/3825525","url":null,"abstract":"<p><p>The diverse roles of cytokines as IL-6 and IL-8 have been studied in terms of their SNPs in many diseases but their role in prostate cancer (PCa) is still uncertain. <i>Aim</i>. To determine the relevance of IL-6 rs1800795 SNP and/or IL-8 rs2227306 SNP with prostate cancer's risk. <i>Subjects and Methods</i>. 40 PCa patients, 40 benign prostate hyperplasia (BPH) patients, and 40-age-matched-control group were enrolled in the study. Genotyping of IL-6 rs1800795 (G/C) SNP and IL-8 rs2227306 (C/T) SNP was determined using real-time PCR. <i>Results</i>. High frequency of IL-6 rs1800795GG and IL-8 rs2227306CC genotypes was noticed among PCa patients with associated OR 10.091 and 8.143, respectively. Comparisons based on allele frequencies revealed that IL-6G and IL-8C alleles are more frequent among PCa patients than other groups. Presence of IL-6 rs1800795G and IL-8 rs2227306C alleles in the same patient increase PCa risk by 16.7 times. Statistical correlations between PSA ratio and both of IL-6 and IL-8 SNP did not show any significant relation among PCa patients. <i>Conclusion</i>. IL-6 rs1800795G and IL-8 rs2227306C alleles could be considered risk factors for PCa development, particularly if presented together. However, no relation was found between both cytokines SNP and severity of prostate cancer.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2021 ","pages":"3825525"},"PeriodicalIF":4.2,"publicationDate":"2021-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39258625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients. Biopsy-Naïve患者获得mri融合活检的最佳PSA阈值。
IF 4.2 Q3 ONCOLOGY Pub Date : 2021-07-01 eCollection Date: 2021-01-01 DOI: 10.1155/2021/5531511
Luke L Wang, Brandon L Henslee, Peter B Sam, Chad A LaGrange, Shawna L Boyle

Objective: The study investigates the prostate-specific antigen threshold for adding targeted, software-based, magnetic resonance imaging-ultrasound fusion biopsy during a standard 12-core biopsy in biopsy-naïve patients. It secondarily explores whether the targeted biopsy is necessary in setting of abnormal digital rectal examination.

Methods: 260 patients with suspected localized prostate cancer with no prior biopsy underwent prostate magnetic resonance imaging and were found to have Prostate Imaging Reporting and Data System score ≥ 3 lesion(s). All 260 patients underwent standard 12-core biopsy and targeted biopsy during the same session. Clinically significant cancer was Gleason ≥3 + 4.

Results: Percentages of patients with prostate-specific antigen 0-1.99, 2-3.99, 4-4.99, 5-5.99, 6-9.99, and ≥10 were 3.0%, 4.7%, 20.8%, 16.9%, 37.7%, and 16.9%, respectively. Cumulative frequency of clinically significant prostate cancer increased with the addition of targeted biopsy compared with standard biopsy alone across all prostate-specific antigen ranges. The difference in clinically significant cancer detection between targeted plus standard biopsy compared to standard biopsy alone becomes statistically significant at prostate-specific antigen >4.3 (p=0.031). At this threshold, combination biopsy detected 20 clinically significant prostate cancers, while standard detected 14 with 88% sensitivity and 20% specificity. Excluding targeted biopsy in setting of a positive digital rectal exam would save 12.3% magnetic resonance imaging and miss 1.8% clinically significant cancers in our cohort.

Conclusions: In biopsy-naïve patients, at prostate-specific antigen >4.3, there is a significant increase in clinically significant prostate cancer detection when targeted biopsy is added to standard biopsy. Obtaining standard biopsy alone in patients with abnormal digital rectal examinations would miss 1.8% clinically significant cancers in our cohort.

目的:本研究调查了在活检幼稚患者的标准12芯活检中添加靶向、基于软件的磁共振成像超声融合活检的前列腺特异性抗原阈值。其次探讨了在直肠指检异常的情况下是否有必要进行靶向活检。方法:对260例既往未经活检的疑似局限性前列腺癌症患者进行前列腺磁共振成像,发现前列腺成像报告和数据系统评分≥ 3处病变。在同一疗程中,所有260名患者均接受了标准的12核心活检和靶向活检。临床显著的癌症为Gleason≥3 + 4.结果:前列腺特异性抗原0-1.99、2-3.99、4-4.99、5-5.99、6-9.99和≥10的患者比例分别为3.0%、4.7%、20.8%、16.9%、37.7%和16.9%。在所有前列腺特异性抗原范围内,与单独的标准活检相比,随着靶向活检的增加,临床显著前列腺癌症的累积频率增加。当前列腺特异性抗原>4.3(p=0.031)时,靶向加标准活检与单独标准活检之间具有临床显著性的癌症检测差异在统计学上具有显著性。在此阈值下,联合活检检测到20种临床显著性前列腺癌,而标准活检检测到14种,灵敏度为88%,特异性为20%。在我们的队列中,在直肠指检呈阳性的情况下排除靶向活检将节省12.3%的磁共振成像,并遗漏1.8%的具有临床意义的癌症。结论:在生物病患者中,当前列腺特异性抗原>4.3时,当将靶向活检添加到标准活检中时,临床显著的前列腺癌症检测显著增加。在我们的队列中,仅对直肠指检异常的患者进行标准活检将错过1.8%的临床意义重大的癌症。
{"title":"Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients.","authors":"Luke L Wang,&nbsp;Brandon L Henslee,&nbsp;Peter B Sam,&nbsp;Chad A LaGrange,&nbsp;Shawna L Boyle","doi":"10.1155/2021/5531511","DOIUrl":"10.1155/2021/5531511","url":null,"abstract":"<p><strong>Objective: </strong>The study investigates the prostate-specific antigen threshold for adding targeted, software-based, magnetic resonance imaging-ultrasound fusion biopsy during a standard 12-core biopsy in biopsy-naïve patients. It secondarily explores whether the targeted biopsy is necessary in setting of abnormal digital rectal examination.</p><p><strong>Methods: </strong>260 patients with suspected localized prostate cancer with no prior biopsy underwent prostate magnetic resonance imaging and were found to have Prostate Imaging Reporting and Data System score ≥ 3 lesion(s). All 260 patients underwent standard 12-core biopsy and targeted biopsy during the same session. Clinically significant cancer was Gleason ≥3 + 4.</p><p><strong>Results: </strong>Percentages of patients with prostate-specific antigen 0-1.99, 2-3.99, 4-4.99, 5-5.99, 6-9.99, and ≥10 were 3.0%, 4.7%, 20.8%, 16.9%, 37.7%, and 16.9%, respectively. Cumulative frequency of clinically significant prostate cancer increased with the addition of targeted biopsy compared with standard biopsy alone across all prostate-specific antigen ranges. The difference in clinically significant cancer detection between targeted plus standard biopsy compared to standard biopsy alone becomes statistically significant at prostate-specific antigen >4.3 (<i>p</i>=0.031). At this threshold, combination biopsy detected 20 clinically significant prostate cancers, while standard detected 14 with 88% sensitivity and 20% specificity. Excluding targeted biopsy in setting of a positive digital rectal exam would save 12.3% magnetic resonance imaging and miss 1.8% clinically significant cancers in our cohort.</p><p><strong>Conclusions: </strong>In biopsy-naïve patients, at prostate-specific antigen >4.3, there is a significant increase in clinically significant prostate cancer detection when targeted biopsy is added to standard biopsy. Obtaining standard biopsy alone in patients with abnormal digital rectal examinations would miss 1.8% clinically significant cancers in our cohort.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2021 ","pages":"5531511"},"PeriodicalIF":4.2,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39220537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Prostate Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1